Two is better than one: Complementing oncolytic virotherapy with gemcitabine to potentiate antitumor immune responses

Research output: Contribution to journalArticlepeer-review

18 Citations (Scopus)

Abstract

Oncolytic viruses (OVs) preferentially infect and kill cancer cells. Additionally, OV-induced immune responses subvert cancer-associated immunosuppression and promote antitumor immunity. We have recently demonstrated that the complementation of oncolytic virotherapy with gemcitabine accentuates its immunostimulatory effects, hence exerting superior antineoplastic activity.

Original languageEnglish
Article numbere27622
JournalOncoImmunology
Volume3
Issue number1
DOIs
Publication statusPublished - 2014

Bibliographical note

Funding Information:
This work was supported by the research grants from the Canadian Institute of Health Research (CIHR), Terry Fox Research

ASJC Scopus Subject Areas

  • Immunology and Allergy
  • Immunology
  • Oncology

Fingerprint

Dive into the research topics of 'Two is better than one: Complementing oncolytic virotherapy with gemcitabine to potentiate antitumor immune responses'. Together they form a unique fingerprint.

Cite this

Gujar, S. A., Clements, D., & Lee, P. W. K. (2014). Two is better than one: Complementing oncolytic virotherapy with gemcitabine to potentiate antitumor immune responses. OncoImmunology, 3(1), Article e27622. https://doi.org/10.4161/onci.27622